Companies Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals (OLMA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Olema Pharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers25th pct.Of 28 peer CEOs
CEO pay, last three years
- $3,152,370FY2023
- $8,130,556FY2024
- $3,178,990FY2025
CEO total pay was $3,178,990 in fiscal 2025, down from $8,130,556 in fiscal 2024.
FY2025: salary $699,920 · bonus $0 · stock awards $0 · option awards $2,002,000
Executives and directors
Sean Bohen · CEOShane Kovacs · CFOShawnte Mitchell · General CounselAndrew Rappaport · Independent DirectorCynthia Butitta · Independent DirectorCyrus L. Harmon, Ph.D · Independent DirectorGorjan Hrustanovic, Ph.D · Independent DirectorGraham Walmsley, M.D., Ph.D · Independent DirectorIan Clark · Independent DirectorSandra Horning, M.D · Independent DirectorScott Garland · Independent DirectorYi Larson · Independent Director
Frequently asked questions
Who was the highest-paid executive at Olema Pharmaceuticals, Inc. in fiscal 2025?
As disclosed, Sean Bohen (President and Chief Executive Officer) was the highest-paid executive at Olema Pharmaceuticals, Inc. in fiscal 2025, with total compensation of $3,178,990.
How does Olema Pharmaceuticals, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Sean Bohen's total compensation ranked at the 25th percentile of Olema Pharmaceuticals, Inc.'s disclosed peer group.
How did shareholders vote on Olema Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 99.05% of shareholders supported Olema Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Olema Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Olema Pharmaceuticals, Inc. reported total board compensation of $506,570 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sean Bohen | $699,920 | $0 | $0 | $2,002,000 | $461,900 | $0 | $15,170 | $3,178,990 |
| President and Chief Executive Officer | ||||||||
| Shawnte Mitchell | 391,875 | 50,000 | 0 | 1,386,000 | 207,900 | 0 | 14,975 | 2,050,750 |
| Chief Legal Officer and Corporate Secretary | ||||||||
| Shane Kovacs | 562,640 | 0 | 0 | 985,600 | 324,925 | 0 | 15,170 | 1,888,335 |
| Chief Operating and Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Sean Bohen | $3,178,990 | $8,130,556 | $3,152,370 | ↓ −4,951,566 |
| Shawnte Mitchell | 2,050,750 | — | — | — |
| Shane Kovacs | 1,888,335 | 4,280,130 | 1,548,370 | ↓ −2,391,795 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program reflects our philosophy of aligning executive compensation with company and individual performance and value creation for the company. We also consider current market practices and trends, and supporting our goals to deliver on our mission and objectives. Executive compensation consists of a base salary and bonus, adjusted based on market trends, and an equity component, including annual refresh grants, which are subject to time-based vesting to incentivize long-term value creation for stockholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Shane Kovacs | Option | — | — | — | — | — | $985,600 |
| Sean Bohen | Option | — | — | — | — | — | 2,002,000 |
| Shawnte Mitchell | Option | — | — | — | — | — | 1,386,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Shane Kovacs | $0 | $0 | $985,600 | 0.0% |
| Sean Bohen | 0 | 0 | 2,002,000 | 0.0% |
| Shawnte Mitchell | 0 | 0 | 1,386,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Shane Kovacs | Option | 10,292 | 7.02 | — |
| Sean Bohen | Option | 33,845 | 7.02 | — |
| Shane Kovacs | Option | 58,334 | 4.87 | — |
| Sean Bohen | Option | 160,417 | 4.87 | — |
| Shane Kovacs | Option | 164,938 | 15.25 | — |
| Shane Kovacs | Option | 320,000 | 4.37 | — |
| Sean Bohen | Option | 336,646 | 15.25 | — |
| Shawnte Mitchell | Option | 450,000 | 4.37 | — |
| Sean Bohen | Option | 650,000 | 4.37 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ian ClarkIndependent · Compensation | $80,000 | — | $65,688 | — | — | $145,688 |
| Cynthia ButittaIndependent · Audit | 61,153 | — | 65,688 | — | — | 126,841 |
| Yi LarsonIndependent · Audit | 60,218 | — | 65,688 | — | — | 125,906 |
| Andrew RappaportIndependent · Compensation | 55,750 | — | 65,688 | — | — | 121,438 |
| Scott GarlandIndependent · Nominating and Corporate Governance | 53,699 | — | 65,688 | — | — | 119,387 |
| Sandra Horning, M.DIndependent · Science and Technology | 52,500 | — | 65,688 | — | — | 118,188 |
| Gorjan Hrustanovic, Ph.DIndependent · Audit | 50,500 | — | 65,688 | — | — | 116,188 |
| Graham Walmsley, M.D., Ph.DIndependent · Science and Technology | 49,000 | — | 65,688 | — | — | 114,688 |
| Cyrus L. Harmon, Ph.DIndependent · Audit | 43,750 | — | 65,688 | — | — | 109,438 |
| Sean Bohen, M.D., Ph.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Raman (Dr.)Independent | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 7,500 / 7,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $506,570 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $506,570 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Olema Pharmaceuticals as a peer
Companies that benchmark against OLMA
6 companies name OLMA as a compensation peer
The list of companies that name OLMA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
PRAX Praxis Precision MedicinesZBIO Zenas BioPharmaAMLX Amylyx Pharmaceuticals (amlx)ALEC AlectorANAB AnaptysBioARCT Arcturus TherapeuticsRCUS Arcus BiosciencesAURA Aura BiosciencesCGEM Cullinan TherapeuticsINBX Inhibrx BiosciencesKALV KalVista PharmaceuticalsKROS Keros TherapeuticsMGTX MeiraGTxNUVB Nuvation BioSNDX Syndax PharmaceuticalsVSTM VerastemVIR Vir BiotechnologyXNCR XencorANNX AnnexonKOD Kodiak SciencesCOGT Cogent BiosciencesERAS ErascaALMS AlumisORIC ORIC PharmaceuticalsRLAY Relay TherapeuticsTERN Terns PharmaceuticalsKURA Kura OncologyARVN Arvinas
Peer reciprocity
The companies Olema Pharmaceuticals, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 3 | Praxis Precision Medicines | 2025 | Marcio Souza | 659,200 | 2,368,125 | 3,691,125 | 1,483,200 | 8,708,648 |
| 4 | MeiraGTx | 2025 | Alexandria Forbes | 840,000 | 5,823,500 | — | — | 8,330,006 |
| 5 | Terns Pharmaceuticals | 2024 | Amy Burroughs | 563,701 | 807,750 | 6,476,968 | 375,000 | 8,240,502 |
| 6 | Vir Biotechnology | 2025 | Marianne De Backer | 950,000 | 2,296,800 | 3,507,360 | 1,002,750 | 7,834,045 |
| 7 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 8 | Arvinas | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 9 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 10 | Alumis | 2025 | Martin Babler | 680,830 | 0 | 4,743,220 | 524,239 | 5,948,289 |
| 11 | Oric Pharmaceuticals | 2025 | Jacob Chacko | 657,500 | 826,000 | 3,634,560 | 434,000 | 5,567,164 |
| 12 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 13 | Cullinan Therapeutics | 2025 | Nadim Ahmed | 698,476 | 1,697,400 | 2,234,340 | 419,086 | 5,100,006 |
| 14 | KalVista Pharmaceuticals | 2025 | Benjamin Palleiko | 477,202 | 3,731,160 | 0 | 0 | 5,094,999 |
| 15 | Kura Oncology | 2025 | Troy Wilson | 700,000 | 0 | 3,297,250 | 630,000 | 4,735,016 |
| 16 | Zenas BioPharma | 2025 | Leon Moulder | 520,000 | 0 | 3,769,200 | 371,800 | 4,661,000 |
| 17 | Relay Therapeutics | 2025 | Sanjiv Patel | 707,846 | 0 | 3,513,900 | 424,708 | 4,646,454 |
| 18 | Erasca | 2025 | Jonathan Lim | 670,400 | 0 | 3,135,250 | 482,688 | 4,298,838 |
| 19 | Aura Biosciences | 2025 | Elisabet de los Pinos | 645,483 | 1,492,378 | 1,513,293 | 284,013 | 3,956,167 |
| 20 | Nuvation Bio | 2025 | David Hung | 650,016 | 0 | 2,674,636 | 536,250 | 3,876,736 |
| 21 | Annexon | 2025 | Douglas Love | 670,833 | 0 | 2,522,260 | 371,250 | 3,579,202 |
| 22 | Olema Pharmaceuticals, Inc. | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 23 | Inhibrx Biosciences | 2025 | Mark Lappe | 695,250 | 0 | 0 | 479,723 | 2,892,473 |
| 24 | Amylyx Pharmaceuticals (amlx) | 2025 | Justin Klee | 686,200 | 650,226 | 817,783 | 548,098 | 2,719,807 |
| 25 | Keros Therapeutics | 2025 | Jasbir Seehra | 700,000 | 1,426,280 | 0 | 398,125 | 2,540,204 |
| 26 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 27 | Verastem | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 28 | Alector | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| 29 | Arcturus Therapeutics | 2025 | Joseph Payne | 750,000 | 0 | 941,000 | 0 | 1,691,000 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | 110% | Options 100 | not disclosed | Aon |
| Alector | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Alumis | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Amylyx Pharmaceuticals (amlx) | 106.5% | not disclosed | No | Pearl Meyer |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Annexon | 100% of target% | not disclosed | not disclosed | Alpine Rewards |
| Arcturus Therapeutics | not disclosed | Options 100 | not disclosed | not disclosed |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Arvinas | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Aura Biosciences | not disclosed | not disclosed | not disclosed | Pay Governance |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Cullinan Therapeutics | not disclosed | not disclosed | not disclosed | Compensia (through June 2025); Pay Governance (since June 2025) |
| Erasca | 120% | Options 100 | not disclosed | Alpine Rewards, LLC |
| Inhibrx Biosciences | not disclosed | Option 100 | not disclosed | not disclosed |
| KalVista Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Keros Therapeutics | 87.5% | RSU 50 · PSU 50 | No | Aon (Human Capital Solutions practice) |
| Kodiak Sciences | 150% | not disclosed | not disclosed | Compensia, Inc. |
| Kura Oncology | 150% | not disclosed | No | Alpine Rewards |
| MeiraGTx | not disclosed | RSU 100 | not disclosed | Total Compensation Solutions |
| Nuvation Bio | not disclosed | not disclosed | not disclosed | FW Cook |
| Oric Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| Praxis Precision Medicines | not disclosed | Option 50 · RSU 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Relay Therapeutics | 100% | Options 100 | not disclosed | Aon |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Terns Pharmaceuticals | 120% | not disclosed | No | Alpine Rewards |
| Verastem | not disclosed | not disclosed | not disclosed | Pearl Meyer |
| Vir Biotechnology | 125% | Options 67 · RSU 33 | not disclosed | Semler Brossy |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Zenas BioPharma | not disclosed | Option 100 | not disclosed | Alpine |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 67,969,902 | 653,979 | 15,867 | 99.05% | Passed |
| 2025 | 2025-06-10 | 54,057,177 | 2,297,482 | 54,317 | 95.92% | Passed |
| 2024 | 2024-06-13 | 45,174,223 | 787,068 | 8,069 | 98.29% | Passed |
| 2023 | 2023-06-15 | 18,713,603 | 1,912,571 | 5,021,093 | 90.73% | Passed |
| 2022 | 2022-06-16 | 21,851,764 | 3,812,824 | 1,922,018 | 85.14% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 99.05%a |
| 2025 | 2025-06-10 | 95.92%b |
| 2024 | 2024-06-13 | 98.29%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| G. Walmsley Graham | Director | 2026-06-18 | A | 29,500 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Rappaport | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Prakash Raman | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Horning | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Yi Larson | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ian Clark | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gorjan Hrustanovic | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Garland | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Harmon | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cynthia Butitta | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BVF PARTNERS L P/IL | Director | 2026-06-18 | A | 29,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Cyrus Harmon | Director | 2026-07-23 | D | 12,500 | 12 | 144,738 | Common, open-market sale | Form 4 ↗ |
| Cyrus Harmon | Director | 2026-07-24 | D | 12,500 | 12 | 146,425 | Common, open-market sale | Form 4 ↗ |
| Jason O'Byrne | Chief Financial Officer | 2026-09-01 | A | 650,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (68 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Sean Bohen. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table” · page 30. As printed: 3,178,990. View filing ↗
- Section 01, Shawnte Mitchell. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 2,050,750. View filing ↗
- Section 01, Shane Kovacs. DEF 14A, filed 2026-04-29. Section “Summary Compensation Table”. As printed: 1,888,335. View filing ↗
- Section 03, Shane Kovacs Option. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Sean Bohen Option. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Shawnte Mitchell Option. DEF 14A, filed 2026-04-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-16. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Ian Clark. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 145,688. View filing ↗
- Section 08, Cynthia Butitta. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 126,841. View filing ↗
- Section 08, Yi Larson. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 125,906. View filing ↗
- Section 08, Andrew Rappaport. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 121,438. View filing ↗
- Section 08, Scott Garland. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 119,387. View filing ↗
- Section 08, Sandra Horning, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 118,188. View filing ↗
- Section 08, Gorjan Hrustanovic, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 116,188. View filing ↗
- Section 08, Graham Walmsley, M.D., Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 114,688. View filing ↗
- Section 08, Cyrus L. Harmon, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 109,438. View filing ↗
- Section 08, Sean Bohen, M.D., Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Raman (Dr.). DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, G. Walmsley Graham 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Rappaport 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Prakash Raman 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sandra Horning 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Yi Larson 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ian Clark 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gorjan Hrustanovic 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Garland 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cyrus Harmon 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cynthia Butitta 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BVF PARTNERS L P/IL 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cyrus Harmon 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Cyrus Harmon 2026-07-24. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason O'Byrne 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-23. Item 5.07 · say-on-pay result. As reported: 99.05% (votes for as printed: 67,969,902). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 95.92% (votes for as printed: 54,057,177). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-14. Item 5.07 · say-on-pay result. As reported: 98.29% (votes for as printed: 45,174,223). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 506,570 + equity 0 + all other 0 = 506,570, summed across the director compensation table rows.
- Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
- Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
- Praxis Precision Medicines, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Praxis Precision Medicines's own proxy. As printed: 8,708,648. View filing ↗
- MeiraGTx, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in MeiraGTx's own proxy. As printed: 8,330,006. View filing ↗
- Terns Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Terns Pharmaceuticals's own proxy. As printed: 8,240,502. View filing ↗
- Vir Biotechnology, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Vir Biotechnology's own proxy. As printed: 7,834,045. View filing ↗
- Syndax Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. View filing ↗
- Arvinas, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. View filing ↗
- AnaptysBio, Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. View filing ↗
- Alumis, Section 10b CEO total. DEF 14A, filed 2026-05-18. CEO total compensation as printed in Alumis's own proxy. As printed: 5,948,289. View filing ↗
- Oric Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Oric Pharmaceuticals's own proxy. As printed: 5,567,164. View filing ↗
- Xencor, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. View filing ↗
- Cullinan Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cullinan Therapeutics's own proxy. As printed: 5,100,006. View filing ↗
- KalVista Pharmaceuticals, Section 10b CEO total. 10-KT/A, filed 2026-04-30. CEO total compensation as printed in KalVista Pharmaceuticals's own proxy. As printed: 5,094,999. View filing ↗
- Kura Oncology, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Kura Oncology's own proxy. As printed: 4,735,016. View filing ↗
- Zenas BioPharma, Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Zenas BioPharma's own proxy. As printed: 4,661,000. View filing ↗
- Relay Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Relay Therapeutics's own proxy. As printed: 4,646,454. View filing ↗
- Erasca, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Erasca's own proxy. As printed: 4,298,838. View filing ↗
- Aura Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Aura Biosciences's own proxy. As printed: 3,956,167. View filing ↗
- Nuvation Bio, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Nuvation Bio's own proxy. As printed: 3,876,736. View filing ↗
- Annexon, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Annexon's own proxy. As printed: 3,579,202. View filing ↗
- Olema Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Olema Pharmaceuticals, Inc.'s own proxy. As printed: 3,178,990. View filing ↗
- Inhibrx Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Inhibrx Biosciences's own proxy. As printed: 2,892,473. View filing ↗
- Amylyx Pharmaceuticals (amlx), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Amylyx Pharmaceuticals (amlx)'s own proxy. As printed: 2,719,807. View filing ↗
- Keros Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Keros Therapeutics's own proxy. As printed: 2,540,204. View filing ↗
- Kodiak Sciences, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. View filing ↗
- Verastem, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Verastem's own proxy. As printed: 2,349,975. View filing ↗
- Alector, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. View filing ↗
- Arcturus Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Arcturus Therapeutics's own proxy. As printed: 1,691,000. View filing ↗
- Section 10a, Verastem reciprocity. DEF 14A. Verastem names Olema Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗